138 related articles for article (PubMed ID: 25168203)
21. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
22. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
Sechaud R; Robeva A; Belleli R; Balez S
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
[TBL] [Abstract][Full Text] [Related]
23. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations.
Magness ST; Bataller R; Yang L; Brenner DA
Hepatology; 2004 Nov; 40(5):1151-9. PubMed ID: 15389867
[TBL] [Abstract][Full Text] [Related]
24. Saikosaponin A of Bupleurum chinense (Chaihu) elevates bone morphogenetic protein 4 (BMP-4) during hepatic stellate cell activation.
Wang X; Wang Q; Burczynski FJ; Kong W; Gong Y
Phytomedicine; 2013 Nov; 20(14):1330-5. PubMed ID: 23969230
[TBL] [Abstract][Full Text] [Related]
25. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.
Zhao XY; Zeng X; Li XM; Wang TL; Wang BE
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):963-8. PubMed ID: 19413596
[TBL] [Abstract][Full Text] [Related]
26. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
27. Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern.
Ruehl M; Erben U; Kim K; Freise C; Dagdelen T; Eisele S; Trowitzsch-Kienast W; Zeitz M; Jia J; Stickel F; Somasundaram R
J Nutr Biochem; 2009 Aug; 20(8):597-606. PubMed ID: 18824344
[TBL] [Abstract][Full Text] [Related]
28. Deferasirox therapy in children with Fanconi aplastic anemia.
Tunç B; Tavil B; Karakurt N; Yarali N; Azik FM; Kara A; Culha V; Ozkasap S
J Pediatr Hematol Oncol; 2012 May; 34(4):247-51. PubMed ID: 22510772
[TBL] [Abstract][Full Text] [Related]
29. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
Bruin GJ; Faller T; Wiegand H; Schweitzer A; Nick H; Schneider J; Boernsen KO; Waldmeier F
Drug Metab Dispos; 2008 Dec; 36(12):2523-38. PubMed ID: 18775980
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology of deferasirox.
Tanaka C
Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
[TBL] [Abstract][Full Text] [Related]
32. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
33. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.
Xu L; Hui AY; Albanis E; Arthur MJ; O'Byrne SM; Blaner WS; Mukherjee P; Friedman SL; Eng FJ
Gut; 2005 Jan; 54(1):142-51. PubMed ID: 15591520
[TBL] [Abstract][Full Text] [Related]
34. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells.
Knight V; Tchongue J; Lourensz D; Tipping P; Sievert W
Hepatology; 2012 Mar; 55(3):879-87. PubMed ID: 22095855
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
36. Deferasirox in thalassemia patients with end-stage renal disease.
Beydoun HG; Saliba AN; Taher AT
Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388
[No Abstract] [Full Text] [Related]
37. Prevention of liver cirrhosis in rats by curcumin.
Bruck R; Ashkenazi M; Weiss S; Goldiner I; Shapiro H; Aeed H; Genina O; Helpern Z; Pines M
Liver Int; 2007 Apr; 27(3):373-83. PubMed ID: 17355460
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.
Ogawa T; Enomoto M; Fujii H; Sekiya Y; Yoshizato K; Ikeda K; Kawada N
Gut; 2012 Nov; 61(11):1600-9. PubMed ID: 22267590
[TBL] [Abstract][Full Text] [Related]
39. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
40. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
